Evgen Pharma focuses on healthy pipeline of clinical programmes

0
44
  • Evgen Pharma to take a closer look at data after COVID-19 study is discontinued
  • Evgen Pharma now has the financial runway to exploit its technology after ‘transformative’ City fundraiser
  • Market Report: FTSE gets jab of confidence as Moderna vaccine starts UK rollout
doctor

Quick facts: Evgen Pharma PLC

Follow

View company profile

Evgen Pharma is a clinical stage drug development company developing sulforaphane-based medicines for the treatment of multiple diseases. Our pipeline is derived from our proprietary Sulforadex(R) technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications.

09 Jul 2021

() will drill down into data from an important trial of its lead asset after the study was discontinued.

SFX-01 was assessed for its potential to treat community-acquired pneumonia, including patients with suspected Coronavirus (COVID-19) infection, as part of the phase II/III STAR trial in Dundee.

The company was told by the independent data committee that an interim analysis of the results did not meet the futility hurdle required to carry on the work.

Recruitment into the trial will therefore be halted. Importantly there were no safety issues, underlining the “excellent safety profile” of SFX-01, Evgen pointed out.

Read more

15 Jun 2021

() said it is building “an exciting and valuable business” with a strengthened senior team and its partner Juvenescence progressing well towards market launch within two years.

The firm completed its first out-licensing deal with Juvenescence for use of Sulforadex technology in non-pharmaceutical markets, which will earn it up to US$10.5mln receivable in milestones with royalties on sales, expected from mid-2023.

Read more

14 Jun 2021

() announced progress on two separate cancer programmes.

The AIM-listed firm is developing SFX-01 for glioblastoma (GBM), which is the most severe classification of glioma, the most common form of brain tumour affecting around five per 100,000 people.

Read more

09 Mar 2021

‘Transformative’ is the word Huw Jones uses to describe the recent GBP11mln fundraising by ().

“It allows us to accelerate some substantial work now,” the company’s CEO says.

Read more

07 Apr 2021

The Market Report with Katie Pilbeam. FTSE 100 open strongly again on vaccine news and a switch in to duller, less cyclical stocks. The blue-chip index was up 62 to 6,885 in early trades.

shares rose 3% as retail investors were allowed to trade for the first time. Some 70,000 small investors bought shares in what has been dubbed the worst IPO ever.

Moderna’s Covid-19 vaccine has started to be rolled out in the UK making it the third version now being administered to people in Britain. Patients in Carmarthenshire in Wales were the first to receive the new vaccine.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is…

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash…

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: FTSE gets jab of confidence as Moderna vaccine starts UK rollout

The Market Report with Katie Pilbeam. FTSE 100 open strongly again on vaccine news and a switch in to duller, less cyclical stocks. The blue-chip index was up 62 to 6,885 in early trades.

Deliveroo shares rose 3% as retail investors were allowed to trade for the first time. Some 70,000…

on 7/4/21

2 min read

LEAVE A REPLY

Please enter your comment!
Please enter your name here